SFT-404

SFT-404 is an investigational inhaled therapy being developed by Softhale, a subsidiary of invoX Pharma, for the treatment of Idiopathic Pulmonary Fibrosis (IPF). The drug is delivered using the proprietary Softhaler® inhalation platform, a high-performance soft mist inhaler (SMI) technology designed to optimize lung deposition and patient adherence. SFT-404 is currently in Phase 1 clinical development, representing an effort to provide a localized, inhaled treatment option for fibrotic lung disease, potentially reducing systemic side effects associated with oral IPF therapies. The specific active pharmaceutical ingredient (API) has not been publicly disclosed, but the program leverages the Softhaler technology to improve the delivery and efficacy of treatments for chronic respiratory and fibrotic lung diseases.